Galena Biopharma Inc. (GALE)

5.72
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 5.72
Open 5.72
Day Low/High 5.56 / 5.85
52 Wk Low/High 3.43 / 19.80
Volume 55.42K
Avg Volume 886.60K
Exchange NASDAQ
Shares Outstanding 45.71M
Market Cap 11.98M
EPS -2,128.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Notable Wednesday Option Activity: GALE, WSTC, SEAS

Notable Wednesday Option Activity: GALE, WSTC, SEAS

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Galena Biopharma Inc , where a total of 10,365 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 66.9% of GALE's average daily trading volume over the past month of 1.5 million shares.

Galena Biopharma Announces Notice Of Allowance Of U.S. Patent For NeuVax™ (nelipepimut-S)

Galena Biopharma Announces Notice Of Allowance Of U.S. Patent For NeuVax™ (nelipepimut-S)

Issued Patent Will Cover Multiple Additional Claims Around the Use of NeuVax

Galena Biopharma Presents Observational Study Data In Gastric Cancer Patients At The ASCO 2016 Gastrointestinal Cancers Symposium

Galena Biopharma Presents Observational Study Data In Gastric Cancer Patients At The ASCO 2016 Gastrointestinal Cancers Symposium

Data Confirms Patient Population Eligibility for Planned Phase 2 Clinical Study of NeuVax™ (nelipepimut-S) in Gastric Cancer to be Conducted in Partnership With Dr. Reddy's Laboratories Ltd.

Galena Biopharma Provides 2016 Outlook

Galena Biopharma Provides 2016 Outlook

Company Enters 2016 With Focus on Immuno-Oncology Clinical Pipeline

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.

Galena Biopharma To Sell Zuplenz® (ondansetron) Oral Soluble Film, Completing Divestiture Of Commercial Operations

Galena Biopharma To Sell Zuplenz® (ondansetron) Oral Soluble Film, Completing Divestiture Of Commercial Operations

Zuplenz to be Sold to Midatech Pharma Plc for a Potential of $23.65 Million Net Payable to Galena Biopharma

Galena Biopharma Completes Divestiture Of Abstral(R) (fentanyl) Sublingual Tablets As Part Of Strategic Focus On Its Immunotherapy Pipeline

Galena Biopharma Completes Divestiture Of Abstral(R) (fentanyl) Sublingual Tablets As Part Of Strategic Focus On Its Immunotherapy Pipeline

Total Transaction Value of Up to $12 Million With $8 Million Cash Upfront and an Additional $4 Million Based on Achievement of Certain Sales Milestones

Galena Biopharma (GALE) Stock Rating Upgraded at Oppenheimer

Galena Biopharma (GALE) Stock Rating Upgraded at Oppenheimer

Galena Biopharma (GALE) stock was upgraded to 'outperform' from 'perform' at Oppenheimer on Thursday.

Galena Biopharma (GALE) Stock Declines on Earnings Miss

Galena Biopharma (GALE) Stock Declines on Earnings Miss

Galena Biopharma (GALE) stock is falling on Tuesday after the company reported a 2015 third quarter earnings loss that was wider than analysts expected.